OncoMed, Fluidigm to Analyze Tumor Cell Populations | GenomeWeb

NEW YORK (GenomeWeb News) – OncoMed Pharmaceuticals and Fluidigm have entered into a collaboration to use microfluidic tools to analyze the heterogeneity of tumor cells, including cancer stem cells, the companies said yesterday.

The partnership will combine Fluidigm's microfluidic platforms with OncoMed's cancer stem cell sorting technology to generate tools to analyze, quantify and develop treatments directed at a highly tumorigenic cell population, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.